RESUMEN
Aromatic amines are an important class of human carcinogens found ubiquitously in our environment. It is estimated that 1 in 8 of all known or suspected human carcinogens is or can be converted into an aromatic amine, making the elucidation of their mechanisms of toxicity a top public health priority. Decades of research into aromatic amine carcinogenesis revealed a complex bioactivation process where Phase I and Phase II drug metabolizing enzymes catalyze N-oxidation and subsequent conjugation reactions generating the highly electrophilic nitrenium intermediate that reacts with and forms adducts on cellular macromolecules. Although aromatic amine-DNA adducts were believed to be the main driver of cancer formation, several studies have reported a lack of correlation between levels of DNA adducts and tumors. Using genetically modified mouse models, our laboratory and others observed several instances where levels of conventionally measured DNA adducts failed to correlate with liver tumor incidence following exposure to the model aromatic amine procarcinogen 4-aminobiphenyl. In this review we first provide a historical overview of the studies that led to a proposed mechanism of carcinogenesis caused by aromatic amines, where their bioactivation to form DNA adducts represents the central driver of this process. We then highlight recent mechanistic studies using 4-aminobiphenyl that are inconsistent with this mechanism which suggest novel drivers of aromatic amine carcinogenesis.
Asunto(s)
Aminas/toxicidad , Compuestos de Aminobifenilo/toxicidad , Carcinógenos/toxicidad , Neoplasias/inducido químicamente , Aminas/farmacocinética , Compuestos de Aminobifenilo/farmacocinética , Animales , Carcinogénesis , Carcinógenos/farmacocinética , Aductos de ADN , Humanos , Inactivación MetabólicaRESUMEN
4-Aminobiphenyl (4-ABP) which is primarily formed during tobacco combustion and overheated meat is a major carcinogen responsible for various cancers. Its adducted form, N-deoxyguanosine-C8-4-aminobiphenyl (dG-C8-4-ABP), has long been employed as a biomarker for assessment of the risk for cancer. In this review, the metabolism and carcinogenisity of 4-ABP will be discussed, followed by a discussion of the current common approaches of analyzing dG-C8-4-ABP. The major part of this review will be on the history and recent development of key methods for detection and quantitation of dG-C8-4-ABP in complex biological samples and their biological applications, from the traditional 2P-postlabelling and immunoassay methods to modern liquid chromatography-mass spectrometry (LC-MS) with the latter as the focus. Many vital biological discoveries based on dG-C8-4-ABP have been published by using the nanoLC-MS with column switching platform in our laboratory, which has also been adopted and further improved by many other researchers. We hope this review can provide a perspective of the challenges that had to be addressed in reaching our present goals and possibly bring new ideas for those who are still working on the frontline of DNA adducts area.
Asunto(s)
Compuestos de Aminobifenilo/análisis , Biomarcadores/análisis , Cromatografía Liquida/métodos , Desoxiguanosina/análogos & derivados , Espectrometría de Masas/métodos , Compuestos de Aminobifenilo/farmacocinética , Animales , Desoxiguanosina/análisis , Desoxiguanosina/farmacocinética , Humanos , Límite de Detección , Modelos Lineales , Ratones , Técnicas Analíticas Microfluídicas , Exposición Profesional , Distribución TisularRESUMEN
The rabbit was the initial animal model to investigate the acetylation polymorphism expressed in humans. Use of the rabbit model is compromised by lack of a rapid non-invasive method for determining acetylator phenotype. Slow acetylator phenotype in the rabbit results from deletion of the N-acetyltransferase 2 (NAT2) gene. A relatively quick and non-invasive method for identifying the gene deletion was developed and acetylator phenotypes confirmed by measurement of N- and O-acetyltransferase activities in hepatic cytosols. Rabbit liver cytosols catalyzed the N-acetylation of sulfamethazine (p = 0.0014), benzidine (p = 0.0257), 4-aminobiphenyl (p = 0.0012), and the O-acetylation of N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP; p = 0.002) at rates significantly higher in rabbits possessing NAT2 gene than rabbits with NAT2 gene deleted. In contrast, hepatic cytosols catalyzed the N-acetylation of p-aminobenzoic acid (an N-acetyltransferase 1 selective substrate) at rates that did not differ significantly (p > 0.05) between rabbits positive and negative for NAT2. The new NAT2 genotyping method facilitates use of the rabbit model to investigate the role of acetylator polymorphism in the metabolism of aromatic and heterocyclic amine drugs and carcinogens.
Asunto(s)
Arilamina N-Acetiltransferasa/genética , Carcinógenos/farmacocinética , Técnicas de Genotipaje/métodos , Polimorfismo Genético , Acetilación , Compuestos de Aminobifenilo/farmacocinética , Animales , Arilamina N-Acetiltransferasa/metabolismo , Bencidinas/farmacocinética , Citosol/enzimología , Genotipo , Conejos , Sulfametazina/farmacocinéticaRESUMEN
Genetic polymorphisms in human N-acetyltransferase 2 (NAT2) modify the metabolism of numerous drugs and carcinogens. These genetic polymorphisms modify both drug efficacy and toxicity and cancer risk associated with carcinogen exposure. Previous studies have suggested phenotypic heterogeneity among different NAT2 slow acetylator genotypes. NAT2 phenotype was investigated in vitro and in situ in samples of human hepatocytes obtained from various NAT2 slow and intermediate NAT2 acetylator genotypes. NAT2 gene dose response (NAT2*5B/*5B > NAT2*5B/*6A > NAT2*6A/*6A) was observed towards the N-acetylation of the NAT2-specific drug sulfamethazine by human hepatocytes both in vitro and in situ. N-acetylation of 4-aminobiphenyl, an arylamine carcinogen substrate for both N-acetyltransferase 1 and NAT2, showed the same trend both in vitro and in situ although the differences were not significant (p > 0.05). The N-acetylation of the N-acetyltransferase 1-specific substrate p-aminobenzoic acid did not follow this trend. In comparisons of NAT2 intermediate acetylator genotypes, differences in N-acetylation between NAT2*4/*5B and NAT2*4/*6B hepatocytes were not observed in vitro or in situ towards any of these substrates. These results further support phenotypic heterogeneity among NAT2 slow acetylator genotypes, consistent with differential risks of drug failure or toxicity and cancer associated with carcinogen exposure.
Asunto(s)
Arilamina N-Acetiltransferasa/genética , Arilamina N-Acetiltransferasa/metabolismo , Heterogeneidad Genética , Hepatocitos/fisiología , Ácido 4-Aminobenzoico/farmacocinética , Compuestos de Aminobifenilo/farmacocinética , Células Cultivadas , Criopreservación , Haplotipos , Humanos , Sulfametazina/farmacocinéticaRESUMEN
4-Aminobiphenyl (ABP), a prototypical aromatic amine carcinogen in rodents and humans, requires bioactivation to manifest its toxic effects. A traditional model of ABP bioactivation, based on in vitro enzyme kinetic evidence, had postulated initial N-hydroxylation by the cytochrome P450 isoform CYP1A2. This is followed by phase 2 O-conjugation and hydrolysis to form a reactive nitrenium ion that covalently binds to DNA and produces tumor-initiating mutations. However, Cyp1a2(-/-) mice still possess significant liver ABP N-hydroxylation activity, DNA damage, and incidence of ABP-induced liver tumors, and in vivo induction of CYP1A2 paradoxically reduces levels of ABP-induced DNA damage. Competing ABP detoxification pathways can include N-acetylation by arylamine N-acetyltransferase 1 (NAT1) and/or NAT2; however, wild-type and Nat1/2(-/-) mice have similar in vivo ABP clearance rates. Together, these studies suggest the existence of novel ABP bioactivating and clearance/detoxification enzymes. In the present study, we detected similar reductions in Vmax for ABP N-hydroxylation by liver microsomes from Cyp1a2(-/-) and Cyp2e1(-/-) mice when compared with wild-type mice. In addition, recombinant mouse CYP1A2 and CYP2E1 were both able to N-hydroxylate ABP in mouse hepatoma cells. However, the in vivo clearance of ABP was significantly reduced in Cyp1a2(-/-) but not in Cyp2e1(-/-) mice. Our results support a significant role for CYP2E1 as a novel ABP N-oxidizing enzyme in adult mice, and suggest a more important contribution of CYP1A2 to the in vivo plasma clearance and thus detoxification of ABP.
Asunto(s)
Compuestos de Aminobifenilo/metabolismo , Citocromo P-450 CYP1A2/genética , Citocromo P-450 CYP1A2/metabolismo , Citocromo P-450 CYP2E1/genética , Citocromo P-450 CYP2E1/metabolismo , Acetilación , Activación Metabólica/genética , Compuestos de Aminobifenilo/farmacocinética , Animales , Arilamina N-Acetiltransferasa/genética , Arilamina N-Acetiltransferasa/metabolismo , Línea Celular Tumoral , Daño del ADN , Hidroxilación , Isoenzimas/genética , Isoenzimas/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microsomas Hepáticos/enzimologíaRESUMEN
N-acetyltransferase 1 (NAT1) is a phase II metabolic enzyme responsible for the biotransformation of aromatic and heterocyclic amine carcinogens such as 4-aminobiphenyl (ABP). NAT1 catalyzes N-acetylation of arylamines as well as the O-acetylation of N-hydroxylated arylamines. O-acetylation leads to the formation of electrophilic intermediates that result in DNA adducts and mutations. NAT1 is transcribed from a major promoter, NATb, and an alternative promoter, NATa, resulting in mRNAs with distinct 5'-untranslated regions (UTR). NATa mRNA is expressed primarily in the kidney, liver, trachea, and lung while NATb mRNA has been detected in all tissues studied. To determine if differences in 5'-UTR have functional effect upon NAT1 activity and DNA adducts or mutations following exposure to ABP, pcDNA5/FRT plasmid constructs were prepared for transfection of full-length human mRNAs including the 5'-UTR derived from NATa or NATb, the open reading frame, and 888 nucleotides of the 3'-UTR. Following stable transfection of NATb/NAT1*4 or NATa/NAT1*4 into nucleotide excision repair (NER) deficient Chinese hamster ovary cells, N-acetyltransferase activity (in vitro and in situ), mRNA, and protein expression were higher in NATb/NAT1*4 than NATa/NAT1*4 transfected cells (P < 0.05). Consistent with NAT1 expression and activity, ABP-induced DNA adducts and hypoxanthine phosphoribosyl transferase mutants were significantly higher (P < 0.05) in NATb/NAT1*4 than in NATa/NAT1*4 transfected cells following exposure to ABP. These differences observed between NATa and NATb suggest that the 5'-UTRs are differentially regulated.
Asunto(s)
Compuestos de Aminobifenilo/toxicidad , Arilamina N-Acetiltransferasa/genética , Aductos de ADN/efectos de los fármacos , Mutación/efectos de los fármacos , Regiones Promotoras Genéticas/genética , Regiones no Traducidas 5'/genética , Acetilación , Empalme Alternativo , Compuestos de Aminobifenilo/metabolismo , Compuestos de Aminobifenilo/farmacocinética , Animales , Arilamina N-Acetiltransferasa/metabolismo , Biotransformación , Western Blotting , Células CHO , Células COS , Carcinógenos/metabolismo , Carcinógenos/farmacocinética , Carcinógenos/toxicidad , Supervivencia Celular/efectos de los fármacos , Chlorocebus aethiops , Cricetinae , Cricetulus , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Células Hep G2 , Humanos , Hipoxantina Fosforribosiltransferasa/genética , Isoenzimas/genética , Isoenzimas/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
NF-E2-related factor 2 (Nrf2) is a major cytoprotective gene and is a key chemopreventive target against cancer and other diseases. Here we show that Nrf2 faces a dilemma in defense against 4-aminobiphenyl (ABP), a major human bladder carcinogen from tobacco smoke and other environmental sources. Although Nrf2 protected mouse liver against ABP (which is metabolically activated in liver), the bladder level of N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dG-C8-ABP), the predominant ABP-DNA adduct formed in bladder cells and tissues, was markedly higher in Nrf2(+/+) mice than in Nrf2(-/-) mice after ABP exposure. Notably, Nrf2 protected bladder cells against ABP in vitro. Mechanistic investigations showed that the dichotomous effects of Nrf2 could be explained at least partly by upregulation of UDP-glucuronosyltransferase (UGT). Nrf2 promoted conjugation of ABP with glucuronic acid in the liver, increasing urinary excretion of the conjugate. Although glucuronidation of ABP and its metabolites is a detoxification process, these conjugates, which are excreted in urine, are known to be unstable in acidic urine, leading to delivery of the parent compounds to bladder. Hence, although higher liver UGT activity may protect the liver against ABP, it increases bladder exposure to ABP. These findings raise concerns of potential bladder toxicity when Nrf2-activating chemopreventive agents are used in humans exposed to ABP, especially in smokers. We further show that 5,6-dihydrocyclopenta[c][1,2]-dithiole-3(4H)-thione (CPDT) significantly inhibits dG-C8-ABP formation in bladder cells and tissues but does not seem to significantly modulate ABP-catalyzing UGT in liver. Thus, CPDT exemplifies a counteracting solution to the dilemma posed by Nrf2.
Asunto(s)
Compuestos de Aminobifenilo/antagonistas & inhibidores , Factor 2 Relacionado con NF-E2/metabolismo , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/metabolismo , Compuestos de Aminobifenilo/farmacocinética , Compuestos de Aminobifenilo/orina , Animales , Carcinógenos/farmacocinética , Línea Celular Tumoral , Quimioprevención , Citoprotección , Aductos de ADN/antagonistas & inhibidores , Aductos de ADN/biosíntesis , Daño del ADN , Glucuronosiltransferasa/metabolismo , Humanos , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Factor 2 Relacionado con NF-E2/genética , Compuestos de Sulfhidrilo/farmacología , Tionas/farmacología , Células Tumorales Cultivadas , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/genética , Neoplasias de la Vejiga Urinaria/prevención & controlRESUMEN
Public health authorities worldwide have concluded that exposure to environmental tobacco smoke (ETS) causes diseases, including cancer, in adult nonsmokers. The arylamine, 4-aminobiphenyl (4-ABP), has been identified as a human carcinogen. Some publications have suggested that 4-ABP hemoglobin (4-ABP-Hb) adduct levels in nonsmokers are a result of exposure to ETS, whereas others could not confirm these observations. Toxicokinetic and exposure models proposed in this work are used to estimate the concentration of 4-ABP-Hb adducts resulting from ETS exposure that is based on experimental values for respirable suspended particulates (RSP) concentration. Monte Carlo methods were used to obtain estimates of population distributions of 4-ABP-Hb adduct levels resulting from indoor ETS exposure in homes, workplaces, and hospitality environments. It is found that the mean, median, and 95th percentile 4-ABP-Hb adduct steady-state levels of 0.4-1.4, 0.2-1.0, and 0.97-4.63 pg/g Hb, respectively, are estimated from ETS exposure. These 4-ABP-Hb adduct levels from ETS exposure account for approximately 1-4% of the median levels reported for nonsmokers, explaining, in part, contradictory literature data on 4-ABP-Hb adduct levels in nonsmokers. No risk assessment of ETS or 4-ABP was conducted in this work, consequently the known health effects of ETS are neither confirmed or challenged and our conclusions are limited to the determination that ETS is not a major source of 4-ABP-Hb adduct levels in non-smokers.
Asunto(s)
Compuestos de Aminobifenilo/metabolismo , Carcinógenos/metabolismo , Exposición a Riesgos Ambientales , Monitoreo del Ambiente/métodos , Hemoglobinas/metabolismo , Contaminación por Humo de Tabaco/efectos adversos , Adulto , Compuestos de Aminobifenilo/farmacocinética , Animales , Carcinógenos/farmacocinética , Femenino , Hemoglobinas/análisis , Hemoglobinas/química , Humanos , Masculino , Modelos Biológicos , Método de MontecarloRESUMEN
Bronchial epithelial cells express xenobiotic-metabolizing enzymes (XMEs) that are involved in the biotransformation of inhaled toxic compounds. The activities of these XMEs in the lung may modulate respiratory toxicity and have been linked to several diseases of the airways. Arylamine N-acetyltransferases (NAT) are conjugating XMEs that play a key role in the biotransformation of aromatic amine pollutants such as the tobacco-smoke carcinogens 4-aminobiphenyl (4-ABP) and beta-naphthylamine (beta-NA). We show here that functional human NAT1 or its murine counterpart Nat2 are present in different lung epithelial cells i.e. Clara cells, type II alveolar cells and bronchial epithelial cells, thus indicating that inhaled aromatic amines may undergo NAT-dependent biotransformation in lung epithelium. Exposure of these cells to pathophysiologically relevant amounts of oxidants known to contribute to lung dysfunction, such as H(2)O(2) or peroxynitrite, was found to impair the NAT1/Nat2-dependent cellular biotransformation of aromatic amines. Genetic and non genetic impairment of intracellular NAT enzyme activities has been suggested to compromise the important detoxification pathway of aromatic amine N-acetylation and subsequently to contribute to an exacerbation of untoward effects of these pollutants on health. Our study suggests that oxidative/nitroxidative stress in lung epithelial cells, due to air pollution and/or inflammation, could contribute to local and/or systemic dysfunctions through the alteration of the functions of pulmonary NAT enzymes.
Asunto(s)
Arilamina N-Acetiltransferasa/metabolismo , Bronquios/enzimología , Oxidantes/farmacología , 2-Naftilamina/farmacocinética , Acetilación , Compuestos de Aminobifenilo/farmacocinética , Arilamina N-Acetiltransferasa/antagonistas & inhibidores , Biotransformación , Bronquios/citología , Células Cultivadas , Cromatografía Líquida de Alta Presión , Electroforesis en Gel de Poliacrilamida , Células Epiteliales/enzimología , Humanos , Peróxido de Hidrógeno/farmacología , Ácido Peroxinitroso/farmacologíaRESUMEN
A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.
Asunto(s)
Acetamidas/síntesis química , Amidas/síntesis química , Compuestos de Aminobifenilo/síntesis química , Benzoatos/síntesis química , Antagonistas del Receptor de Bradiquinina B1 , Encéfalo/metabolismo , Ciclopropanos/síntesis química , Médula Espinal/metabolismo , Acetamidas/farmacocinética , Acetamidas/farmacología , Administración Oral , Amidas/farmacocinética , Amidas/farmacología , Compuestos de Aminobifenilo/farmacocinética , Compuestos de Aminobifenilo/farmacología , Analgésicos/síntesis química , Analgésicos/química , Analgésicos/farmacología , Animales , Animales Modificados Genéticamente , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Benzoatos/farmacocinética , Benzoatos/farmacología , Disponibilidad Biológica , Barrera Hematoencefálica/metabolismo , Células CHO , Chlorocebus aethiops , Cricetinae , Cricetulus , Ciclopropanos/farmacocinética , Ciclopropanos/farmacología , Femenino , Humanos , Macaca mulatta , Masculino , Ratones , Conejos , Ensayo de Unión Radioligante , Ratas , Especificidad de la Especie , Relación Estructura-ActividadRESUMEN
Cigarette smoking is the predominant risk factor for bladder cancer. Aromatic amines such as 4-aminobiphenyl (ABP) is the major carcinogens found in tobacco smoke. Although it is generally accepted that ABP is metabolically activated via N-hydroxylation by CYP1A2 in human liver, previous studies using Cyp1a2-null mice indicated the involvement of other enzyme(s). Here we found that CYP2A13 can metabolically activate ABP to show genotoxicity by Umu assay. The K(m) and V(max) values for ABP N-hydroxylation by recombinant CYP2A13 in E. coli were 38.5 +/- 0.6 microM and 7.8 +/- 0.0 pmol/min/pmol CYP, respectively. The K(m) and V(max) values by recombinant CYP1A2 were 9.9 +/- 0.9 microM and 39.6 +/- 0.9 pmol/min/pmol CYP, respectively, showing 20-fold higher intrinsic clearance than CYP2A13. In human bladder, CYP2A13 mRNA, but not CYP1A2, is expressed at a relatively high level. Human bladder microsomes showed ABP N-hydroxylase activity (K(m) = 34.9 +/- 4.7 microM and V(max) = 57.5 +/- 1.9 pmol/min/mg protein), although the intrinsic clearance was 5-fold lower than that in human liver microsomes (K(m) = 33.2 +/- 2.0 microM and V(max) = 293.9 +/- 5.8 pmol/min/mg protein). The activity in human bladder microsomes was prominently inhibited by 8-methoxypsoralen, but not by fluvoxamine, anti-CYP1A2 or anti-CYP2A6 antibodies. CYP2S1, which is expressed in human bladder and has relatively high amino acid identities with CYP2As, did not show detectable ABP N-hydroxylase activity. In conclusion, although the enzyme responsible for ABP N-hydroxylation in human bladder microsomes could not be determined, we found that CYP2A13 metabolically activates ABP.
Asunto(s)
Compuestos de Aminobifenilo/farmacocinética , Hidrocarburo de Aril Hidroxilasas/metabolismo , Vejiga Urinaria/enzimología , Hidrocarburo de Aril Hidroxilasas/genética , Secuencia de Bases , Biotransformación , Cartilla de ADN , Humanos , Microsomas/enzimología , Oxigenasas de Función Mixta/metabolismo , ARN Mensajero/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Arylamine N-acetyltransferases (NATs) catalyze the biotransformation of a number of aromatic and heterocyclic amines, many of which are procarcinogenic agents. Interestingly, these enzymes are binary in nature, participating in both detoxification and activation reactions, and thus it is unclear what role NATs actually play in either preventing or enhancing toxic responses. The ultimate direction may be substrate-specific and dependent on its tissue-specific metabolism by competing, but genetically variable, drug-metabolizing enzymes. To investigate the effect of N-acetylation on the metabolism of some classical procarcinogenic arylamines, we have used our double knockout Nat1/2(-/-) mouse model to test both in vitro activity and the in vivo clearance of some of these agents. As expected, N-acetylation activity was undetectable in tissue cytosol preparations from Nat1/2(-/-) mice for 4-aminobiphenyl (ABP) and 2-aminofluorene (AF), whereas significant levels were measured in all wild-type tissue cytosols tested, indicating the widespread metabolism of these agents. Nat1/2(-/-) mice displayed a variable response with respect to in vivo pharmacokinetics. AF appeared to be most severely compromised, with a 3- to 4-fold increased area under the curve (AUC), whereas the clearance of ABP was found to be less dependent on N-acetylation, with no difference in ABP-AUC between wild-type and knockout animals. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine was neither N-acetylated nor was its clearance affected by NAT genotype, signifying a dependence on other drug-metabolizing enzymes. The elucidation of the role that N-acetylation plays in the clearance of procarcinogenic agents is the first step in attempting to correlate metabolism by NATs to toxic outcome prevention or augmentation.
Asunto(s)
Aminas/metabolismo , Arilamina N-Acetiltransferasa/deficiencia , Carcinógenos/metabolismo , Aminas/administración & dosificación , Aminas/farmacocinética , Compuestos de Aminobifenilo/administración & dosificación , Compuestos de Aminobifenilo/metabolismo , Compuestos de Aminobifenilo/farmacocinética , Animales , Área Bajo la Curva , Arilamina N-Acetiltransferasa/genética , Arilamina N-Acetiltransferasa/metabolismo , Biotransformación , Carcinógenos/administración & dosificación , Carcinógenos/farmacocinética , Cromatografía Líquida de Alta Presión , Fluorenos/administración & dosificación , Fluorenos/metabolismo , Fluorenos/farmacocinética , Humanos , Imidazoles/administración & dosificación , Imidazoles/metabolismo , Imidazoles/farmacocinética , Tasa de Depuración Metabólica , Ratones , Ratones Endogámicos , Ratones NoqueadosRESUMEN
Age-related changes in the expression of xenobiotic biotransformation enzymes can result in differences in the rates of chemical activation and detoxification, affecting responses to the therapeutic and/or toxic effects of chemicals. Despite recognition that children and adults may exhibit differences in susceptibility to chemicals, information about when in development specific biotransformation enzymes are expressed is incomplete. N-acetyltransferases (NATs) are phase II enzymes that catalyze the acetylation of arylamine and hydrazine carcinogens and therapeutic drugs. The postnatal expression of NAT1 and NAT2 was investigated in C57Bl/6 mice. Hepatic NAT1 and NAT2 messenger RNAs (mRNAs) increased with age from neonatal day (ND) 4 to adult in a nonlinear fashion. The presence of functional proteins was confirmed by measuring NAT activities with the isoform selective substrates p-aminobenzoic acid and isoniazid, as well as the carcinogens 2-aminofluorene and 4-aminobiphenyl (4ABP). Neonatal liver was able to acetylate all of the substrates, with activities increasing with age. Protein expression of CYP1A2, another enzyme involved in the biotransformation of arylamines, showed a similar pattern. The genotoxicity of 4ABP was assessed by determining hepatic 4ABP-DNA adducts. There was an age-dependent increase in 4ABP-DNA adducts during the neonatal period. Thus, developmental increases in expression of NAT1 and NAT2 genes in neonates are associated with less 4ABP genotoxicity. The age-related pattern of expression of biotransformation enzymes in mice is consistent with human data for NATs and suggests that this may play a role in developmental differences in arylamine toxicity.
Asunto(s)
Acetiltransferasas , Sistemas de Transporte de Aminoácidos , Compuestos de Aminobifenilo/toxicidad , Proteínas Portadoras/biosíntesis , Mutágenos/toxicidad , Ácido 4-Aminobenzoico/farmacocinética , Ácido 4-Aminobenzoico/farmacología , Envejecimiento , Sistema de Transporte de Aminoácidos A , Compuestos de Aminobifenilo/farmacocinética , Animales , Animales Recién Nacidos , Arilamina N-Acetiltransferasa , Biotransformación , Proteínas Portadoras/genética , Citocromo P-450 CYP1A2/biosíntesis , Aductos de ADN/análisis , Aductos de ADN/efectos de los fármacos , Fluorenos/farmacocinética , Fluorenos/toxicidad , Isoenzimas , Isoniazida/farmacocinética , Isoniazida/farmacología , Hígado/efectos de los fármacos , Hígado/enzimología , Ratones , Ratones Endogámicos C57BL , Mutágenos/farmacocinética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Lead affects almost every system in the body and 4-aminobiphenyl increases the incidence of bladder cancer among human exposed to aromatic amines, but little attention has been paid to the effects of lead (heavy metals) on the distribution and metabolic kinetics of 4-ABP (organic pollutants) in the organisms of the terrestrial ecosystems. In this study, male S.D. rats as model animals drinking tap water with and without lead with i.p. injection of 4-aminophenyl were used to study 4-aminobiphenyl pharmacokinetics with statistical analysis in three types of information systems: (1) hemoglobin adduct in the blood; (2) distribution concentrations in liver, kidney, spleen, testes, heart and lung; (3) relative weights of the six organs. Kinetic equations of 4-aminobiphenyl-hemoglobin adduct for two groups of rats drinking water with and without lead were all linear. Principal components were obtained based on three types of variants: (1) variants of distribution concentrations; (2) variants of relative weights; (3) variants of hemoglobin adduct, distribution concentrations and relative weights. Through a comparison of two groups of principal components, the result implied that lead changed 4-aminobiphenyl distribution kinetics in the six organs, had significant effects on the six organ relative weights, and had also significant effects on all thirteen variants as a whole. Correlation analysis of the principal components showed that lead could not significantly change the relation of hemoglobin adduct with time after dosing 4-aminobiphenyl. However, another result indicated that lead considerably improved the correlation between hemoglobin adduct and the thirteen variants as a whole. This implied that hemoglobin adduct could characterize all the thirteen variants as an index of 4-aminobiphenyl pharmacokinetics for the rats drinking water with lead, which conclusion was not suitable for the rats drinking water without lead. The research indicated that heavy metals existing in the organisms play an important role in the studies on pharmacotoxicology of organic pollutants. Frequently, various xenobiotics (heavy metals and organic pollutants) enter organisms simultaneously, therefore heavy metals should be considered comprehensively in the pharmacotoxicology of organic pollutants in animals in the terrestrial ecosystems theoretically and practically.
Asunto(s)
Compuestos de Aminobifenilo/farmacocinética , Carcinógenos Ambientales/farmacocinética , Hemoglobinas/metabolismo , Plomo/farmacología , Animales , Ecosistema , Riñón/metabolismo , Hígado/metabolismo , Pulmón/metabolismo , Masculino , Miocardio/metabolismo , Ratas , Ratas Sprague-Dawley/metabolismo , Bazo/metabolismo , Testículo/metabolismoRESUMEN
The global genomic repair of DNA adducts was examined in human papillary transitional cell carcinoma (TCC) cell lines after exposure to N:-hydroxy-4-acetylaminobiphenyl (N-OH-AABP), the proximate carcinogenic metabolite of the human bladder carcinogen 4-aminobiphenyl (ABP). (32)P-post-labeling analysis of TCC cultures exposed to N-OH-AABP revealed a major adduct, identified as the 3',5'-bisphosphate derivative of N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dG-C8-ABP). The amount of adduct formation in TCC10 was dependent upon the dose and the duration of exposure and ranged between 1 and 5 adducts/10(7) nucleotides. To test if p53 regulates repair of the dG-C8-ABP adduct in genomic DNA, an isogeneic set of cell lines was obtained by infection of the TCC10 cultures with a retroviral construct expressing a trans-dominant mutant of p53, namely a Val-->Ala mutation at codon 143. The TDM143-TCC10 line expressing the mutant form of p53 was selected. The rate of repair of dG-C8-ABP was compared between TCC10 and TDM143-TCC10 cultures after treatment with 15 microM N-OH-AABP. The rate of disappearance of the adduct was monitored over a period of time after chemical treatment. (32)P-post-labeling analysis of dG-C8-ABP in parental TCC10 showed its rapid removal, the majority of adducts disappearing within 48 h. In contrast to TCC10, TDM143-TCC10 was relatively slower in removal of dG-C8-ABP. After 24 h DNA repair TDM143-TCC10 showed an approximately 3-fold greater amount of dG-C8-ABP compared with TCC10. These results imply that p53 plays a role in the repair of ABP adducts and that in p53 null cells the unrepaired DNA damage could cause accumulation of mutations, which might contribute to increased genomic instability and neoplastic progression.
Asunto(s)
Compuestos de Aminobifenilo/metabolismo , Carcinoma de Células Transicionales/genética , Aductos de ADN/genética , Reparación del ADN/genética , Desoxiguanosina/metabolismo , Genes p53/genética , Neoplasias de la Vejiga Urinaria/genética , Compuestos de Aminobifenilo/farmacocinética , Compuestos de Aminobifenilo/toxicidad , Carcinógenos/metabolismo , Carcinógenos/farmacocinética , Carcinógenos/toxicidad , Carcinoma de Células Transicionales/metabolismo , Aductos de ADN/biosíntesis , Daño del ADN/genética , Desoxiguanosina/análogos & derivados , Desoxiguanosina/farmacocinética , Desoxiguanosina/toxicidad , Genotipo , Humanos , Mutagénesis/genética , Mutación , Reacción en Cadena de la Polimerasa , Transfección , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/genética , Neoplasias de la Vejiga Urinaria/metabolismoRESUMEN
4-Aminobiphenyl (4-ABP), a potent carcinogen in rodents (liver cancer) and human (bladder cancer), is found as an environmental contaminant and in tobacco smoke. Hemoglobin adducts and lung DNA adducts of 4-ABP are found in tobacco smokers. In vitro metabolism studies with human and rat liver microsomes have shown that CYP1A2 is primarily responsible for catalyzing N-hydroxylation, the initial step in the metabolic activation of 4-ABP. To determine whether this P450 is a rate limiting pathway for hepatocarcinogenesis, CYP1A2-null mice were analyzed at 16 months of age and were compared with wild-type mice in their response to 4-ABP using the neonatal mouse bioassay and two different doses of the carcinogen. Overall differences in incidences of hepatocellular adenoma, carcinoma and preneoplastic foci were not significant between either genotypes or 4-ABP doses used, whereas small, but significant, differences were found for specific types of foci. These results suggest that while CYP1A2 levels may not be rate limiting for 4-ABP metabolism to produce tumors and foci, it may modulate the induction process of some types of liver foci in either a positive or negative manner. In vitro studies using CYP1A2-null and wild-type mouse liver microsomes revealed that CYP1A2 is not the sole P450 required for 4-ABP N-hydroxylation and that another, yet to be identified, P450 is likely to be involved.
Asunto(s)
Compuestos de Aminobifenilo/toxicidad , Carcinógenos Ambientales/toxicidad , Citocromo P-450 CYP1A2/fisiología , Neoplasias Hepáticas Experimentales/inducido químicamente , Microsomas Hepáticos/enzimología , Adenoma/inducido químicamente , Adenoma/enzimología , Compuestos de Aminobifenilo/farmacocinética , Animales , Animales Recién Nacidos , Biotransformación , Carcinógenos Ambientales/farmacocinética , Carcinoma/inducido químicamente , Carcinoma/enzimología , Cruzamientos Genéticos , Citocromo P-450 CYP1A2/deficiencia , Citocromo P-450 CYP1A2/genética , Femenino , Humanos , Hidroxilación , Hígado/patología , Neoplasias Hepáticas Experimentales/enzimología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Tamaño de los Órganos/efectos de los fármacos , Lesiones Precancerosas/inducido químicamente , Lesiones Precancerosas/enzimología , Ratas , Receptores de Hidrocarburo de Aril/deficiencia , Receptores de Hidrocarburo de Aril/genética , Especificidad de la Especie , Estómago/enzimología , Estómago/patologíaRESUMEN
Maternal-fetal exchange of the potent tobacco-related human carcinogen, 4-aminobiphenyl, was studied in women nonsmokers and in women smokers as well as in the corresponding fetuses during pregnancy. Smoking status of the women in the study was assessed via questionnaire and measurement by immunoassay of serum cotinine in maternal and fetal blood samples. 4-Aminobiphenyl was extracted from both maternal and fetal blood samples using organic solvent extractions and the released amine was qualitatively and quantitatively characterized by analysis of the samples by high pressure liquid chromatography (HPLC) and gas chromatography coupled with mass spectrometry (GC/MS). Background levels (pg 4-aminobiphenyl/g haemoglobin) of 4-aminobiphenyl-haemoglobin adducts were detected in maternal smokers (mean +/- S.D; 29.6 +/- 16.2 (GC/MS); 23.7 +/- 13.5 (HPLC) and in fetal samples (14.0 +/- 6.5 (GCMS); 10.0 +/- 4.6 (HPLC). Elevated levels of 4-aminobiphenyl-haemoglobin adducts were found in maternal smokers (488 +/- 174 (GC/MS); 423 +/- 154 (HPLC). as well as in the corresponding fetal blood samples (244 +/- 91 (GC/MS); 197 +/- 77 (HPLC). This study confirms that a potent tobacco-related carcinogen, 4-aminobiphenyl, crosses the human placenta and binds to fetal haemoglobin in significantly higher concentrations in smokers when compared to nonsmokers.
Asunto(s)
Compuestos de Aminobifenilo/sangre , Carcinógenos/metabolismo , Sangre Fetal/metabolismo , Hemoglobinas/metabolismo , Fumar/efectos adversos , Compuestos de Aminobifenilo/efectos adversos , Compuestos de Aminobifenilo/farmacocinética , Cromatografía Líquida de Alta Presión , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Exposición Materna , Intercambio Materno-Fetal , EmbarazoRESUMEN
32P-Postlabeling analysis of the bisphosphate derivatives was conducted to characterize the DNA adducts generated from the peroxidase-mediated activation of N-hydroxy-4-acetylaminobiphenyl (N-OH-AABP). Autoradiography of the D1 chromatogram of the postlabeled DNA hydrolysate revealed a major adduct (adduct 1) that migrated at Rf 0.15. An adduct with similar chromatographic characteristics was also obtained by postlabeling the products generated by chemical interaction of: (i) 2',6'-dichlorobenzoyloxy-4-acetylaminobiphenyl with the 3'-monophosphate of deoxyguanosine, and (ii) N-acetoxy-4-acetylaminobiphenyl (N-OAc-AABP) with calf thymus DNA. The adduct derived from chemical reaction exhibited the same mobilities on two-dimensional TLC as that obtained from the peroxidase-mediated DNA binding of N-OH-AABP. Moreover, on HPLC analyses, these bisphosphate derivatives exhibited identical retention times, suggesting that structurally they might be the same. Furthermore, adduct 1 was insensitive to digestion with nuclease P1. In addition to adduct 1, another minor adduct (adduct 2) was also detected in the peroxidase-mediated DNA binding of N-OH-AABP. The adduct 2 in D1 exhibited an Rf of 0.66. Adduct 2 was also observed in the DNA sample chemically interacted with N-OAc-AABP. Both these adducts retained the acetyl moiety, which was confirmed by the presence of radioactivity in the hydrolysate of DNA derived by interaction with N-OAc-[14C-acetyl]AABP (labeled at the N-acetyl group). Based on proton NMR and MS analyses of the 5'-phospho analogs of adducts 1 and 2, the structures of these have been identified as 3-(deoxyguanosine-N2-yl)-4-acetylaminobiphenyl (dG-N2-AABP) and N-(deoxyguanosine-8-yl)-4-acetylaminobiphenyl (dG-C8-AABP). Analyses of the DNA samples obtained from human uroepithelial cells following exposure to N-OH-AABP revealed primarily the non-acetylated derivative N-(deoxyguanosine-8-yl)-4-aminobiphenyl (dG-C8-ABP) with trace amounts of dG-N2-AABP. These results suggest that in the target cells for 4-aminobiphenyl carcinogenesis, the prevalence of the peroxidase mediated activation reaction of N-OH-AABP is relatively minor compared to the acetyltransferase pathway.
Asunto(s)
Compuestos de Aminobifenilo/metabolismo , Carcinógenos/metabolismo , Aductos de ADN/análisis , ADN/efectos de los fármacos , Peroxidasa de Rábano Silvestre/metabolismo , Acetilación , Compuestos de Aminobifenilo/análisis , Compuestos de Aminobifenilo/farmacocinética , Compuestos de Aminobifenilo/toxicidad , Animales , Biotransformación , Carcinógenos/farmacocinética , Carcinógenos/toxicidad , Bovinos , Células Cultivadas , ADN/metabolismo , Aductos de ADN/biosíntesis , Desoxiguanosina/análogos & derivados , Desoxiguanosina/análisis , Desoxiguanosina/metabolismo , Epitelio/efectos de los fármacos , Epitelio/metabolismo , Peroxidasa de Rábano Silvestre/farmacología , Humanos , Peróxido de Hidrógeno/metabolismo , Peróxido de Hidrógeno/farmacología , Marcaje Isotópico , Oxidación-Reducción , Radioisótopos de Fósforo , Sistema Urinario/efectos de los fármacos , Sistema Urinario/metabolismoRESUMEN
To obtain further knowledge of the metabolic fate of carcinogenic 4-aminobiphenyl (ABP) and 4-acetyl-aminobiphenyl (AABP) in intact guinea pig liver, we performed in situ liver perfusion using a recirculation method. Following a biexponential disappearance of ABP from the perfusate, not only AABP but also its secondary metabolites 4'-hydroxy AABP (4'-OH AABP) and 4-glycolylaminobiphenyl (GABP) appeared as the major metabolites. 4'-Hydroxy ABP (4'-OH ABP) was also detected in the perfusate as another predominant metabolite, while N-hydroxy ABP (N-OH ABP) as a minor one. Most of these metabolites, except for AABP and GABP, found in both perfusate and bile were conjugated with glucuronic acid. In addition, considerable amounts of all the metabolites were also detected in either unconjugated or conjugated form in a homogenate of the liver tissue after perfusion. When AABP was infused, an almost similar metabolic profile to that of ABP was obtained, but the amount of ABP was quite small and N-OH AABP rather than N-OH ABP was found. These results demonstrate that both ABP and AABP are rapidly metabolized by a combination of N-acetylation, C- and N-hydroxylations as well as glucuronidation in guinea pig liver.
Asunto(s)
Compuestos de Aminobifenilo/metabolismo , Hígado/metabolismo , Compuestos de Aminobifenilo/farmacocinética , Animales , Biotransformación , Cobayas , Semivida , Técnicas In Vitro , Masculino , PerfusiónRESUMEN
We investigate, through modeling, the impact of interindividual heterogeneity in the metabolism of 4-aminobiphenyl (ABP) and in physiological factors on human cancer risk: A physiological pharmacokinetic model was used to quantify the time course of the formation of the proximate carcinogen, N-hydroxy-4-ABP and the DNA-binding of the active species in the bladder. The metabolic and physiologic model parameters were randomly varied, via Monte Carlo simulations, to reproduce interindividual variability. The sampling means for most parameters were scaled from values developed by Kadlubar et al. (Cancer Res., 51: 4371, 1991) for dogs; variances were obtained primarily from published human data (e.g., measurements of ABP N-oxidation, and arylamine N-acetylation in human liver tissue). In 500 simulations, theoretically representing 500 humans, DNA-adduct levels in the bladder of the most susceptible individuals are ten thousand times higher than for the least susceptible, and the 5th and 95th percentiles differ by a factor of 160. DNA binding for the most susceptible individual (with low urine pH, low N-acetylation and high N-oxidation activities) is theoretically one million-fold higher than for the least susceptible (with high urine pH, high N-acetylation and low N-oxidation activities). The simulations also suggest that the four factors contributing most significantly to interindividual differences in DNA-binding of ABP in human bladder are urine pH, ABP N-oxidation, ABP N-acetylation and urination frequency.